Acta Pharmaceutica Sinica B (Jul 2020)

Crystal structure of SARS-CoV-2 nucleocapsid protein RNA binding domain reveals potential unique drug targeting sites

  • Sisi Kang,
  • Mei Yang,
  • Zhongsi Hong,
  • Liping Zhang,
  • Zhaoxia Huang,
  • Xiaoxue Chen,
  • Suhua He,
  • Ziliang Zhou,
  • Zhechong Zhou,
  • Qiuyue Chen,
  • Yan Yan,
  • Changsheng Zhang,
  • Hong Shan,
  • Shoudeng Chen

DOI
https://doi.org/10.1016/j.apsb.2020.04.009
Journal volume & issue
Vol. 10, no. 7
pp. 1228 – 1238

Abstract

Read online

The outbreak of coronavirus disease (COVID-19) caused by SARS-CoV-2 virus continually lead to worldwide human infections and deaths. Currently, there is no specific viral protein-targeted therapeutics. Viral nucleocapsid protein is a potential antiviral drug target, serving multiple critical functions during the viral life cycle. However, the structural information of SARS-CoV-2 nucleocapsid protein remains unclear. Herein, we have determined the 2.7 Å crystal structure of the N-terminal RNA binding domain of SARS-CoV-2 nucleocapsid protein. Although the overall structure is similar as other reported coronavirus nucleocapsid protein N-terminal domain, the surface electrostatic potential characteristics between them are distinct. Further comparison with mild virus type HCoV-OC43 equivalent domain demonstrates a unique potential RNA binding pocket alongside the β-sheet core. Complemented by in vitro binding studies, our data provide several atomic resolution features of SARS-CoV-2 nucleocapsid protein N-terminal domain, guiding the design of novel antiviral agents specific targeting to SARS-CoV-2.

Keywords